Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results

Stępień, Adam; Dabrowska, Natalia L.; Maciagowska, Marzena; Macoch, Renata Piusinska; Zołocińska, Aleksandra; Mazur, S.; Siennicka, Katarzyna; Frankowska, Emilia; Kidziński, Rafał; Chalimoniuk, Małgorzata; Pojda, Zygmunt

doi:10.1155/2016/5302120

Cited by 40 publications

(40 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By this mechanism, ADSCs have not only been successful at treating diseases in animal models but also in humans. Recently, Stepien et al (2016) used ADSCs to treat Multiple Sclerosis in human; they showed that intrathecal treatment of ADSCs was a suitable therapy for cases with aggressive disease progression (Stepien et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus

Pham

et al. 2016

Biomed Res Ther

View full text Add to dashboard Cite

Introduction: Type 2 diabetes mellitus (T2D) is the most common form of diabetes mellitus, accounting for 90% of diabetes mellitus in patients. At the present time, although T2D can be treated by various drugs and therapies using insulin replacement, reports have shown that complications including microvascular, macrovascular complications and therapy resistance can occur in patients on long term treatment. Stem cell therapy is regarded as a promising therapy for diabetes mellitus, including T2D. The aim of this study was to evaluate the safety and therapeutic effect of expanded autologous adipose derived stem cell (ADSC) transplantation for T2D treatment; the pilot study included 3 patients who were followed for 3 months. Methods: The ADSCs were isolated from stromal vascular fractions, harvested from the belly of the patient,and expanded for 21 days per previously published studies. Before transplantation, ADSCs were evaluated for endotoxin, mycoplasma contamination, and karyotype.All patients were transfused with ADSCs at 1-2x10 6 cells/kg of body weight.Patients were evaluated for criteria related to transplantation safety and therapeutic effects; these included fever, blood glucose level before transplantation of ADSCs, and blood glucose level after transplantation (at 1, 2 and 3 months). Results: The results showed that all samples of ADSCs exhibited the MSC phenotype with stable karyotype (2n=46), there was no contamination of mycoplasma, and endotoxin levels were low (<0.25 EU/mL). No adverse effects were detected after 3 months of transplantation. Decreases of blood glucose levels were recorded in all patients. Conclusion: The findings from this initial study show that expanded autologous ADSCs may be a promising treatment for T2D.

show abstract

Section: Discussionmentioning

confidence: 99%

Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus

Pham

et al. 2016

Biomed Res Ther

View full text Add to dashboard Cite

show abstract

“…After 18 months of follow-up, ASCs were shown to be safe, but with no significant benefits having been reported. [58] Notably, there was no disease progression, and the authors noted that although this was an attractive strategy, the treatment should be reserved for patients with aggressive disease progression. In the second study, a blinded randomised trial, 26 patients were treated with either low-dose/high-dose ASCs or placebo.…”

Section: Researchmentioning

confidence: 99%

Stem cell therapy for neurological disorders

et al. 2019

View full text Add to dashboard Cite

show abstract

“…There is evidence supporting a role the antiinflammatory capacity of ADSCs for this devastating disorder [99][100][101], as well as their neuron-rebuilding capability. Indeed, both SVF and ADSCs appear to be effective in animal models of this disease [99,[102][103][104][105][106][107][108][109][110][111]. Bowles, et al, reported an advantage of SVF over ADSCs in the experimental autoimmune encephalomyelitis (EAE) model in the mouse [103,104].…”

Section: Msmentioning

confidence: 99%

Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients

Duma¹,

Kopyov²,

Kopyov³

et al. 2019

Mol Biol Rep

View full text Add to dashboard Cite

We have chosen to test the safety of human intracerebroventricular (ICV) brain injections of autologous non-geneticallymodified adipose-derived stromal vascular fraction (ADSVF). In this IRB-approved trial, 24 patients received ICV ADSVF via an implanted reservoir between 5/22/14 and 5/22/17. Seven others were injected via their ventriculo-peritoneal shunts. Ten patients had Alzheimer's disease (AD), 6 had amyotrophic lateral sclerosis (ALS), 6 had progressive multiple sclerosis (MS-P), 6 had Parkinson's "Plus" (PD+), 1 had spinal cord injury, 1 had traumatic brain injury, and 1 had stroke. Median age was 74 (range 41-83). Injections were planned every 2-3 months. Thirty-one patients had 113 injections. Patients received SVF injection volumes of 3.5-20 cc (median:4 cc) containing 4.05 × 10 5 to 6.2 × 10 7 cells/cc, which contained an average of 8% hematopoietic and 7.5% adipose stem cells. Follow-up ranged from 0 to 36 months (median: 9.2 months). MRIs post injection(s) were unchanged, except for one AD patient whose hippocampal volume increased from < 5th percentile to 48th percentile (NeuroQuant ® volumetric MRI). Of the 10 AD patients, 8 were stable or improved in tests of cognition. Two showed improvement in P-tau and ß-amyloid levels. Of the 6 MS-P patients all are stable or improved. Four of 6 ALS patients died of disease progression. Twelve of 111 injections (11%) led to 1-4 days of transient meningismus, and mild temperature elevation, which resolved with acetaminophen and/or dexamethasone. Two (1.8% of injections) required hospitalization for these symptoms. One patient (0.9% of injections) had his reservoir removed and later replaced for presumed infection. In this Phase 1 safety trial, ADSVF was safely injected into the human brain ventricular system in patients with no other treatment options. Secondary endpoints of clinical improvement or stability were particularly promising in the AD and MS-P groups. These results will be submitted for a Phase 2 FDA-approved trial.

show abstract

Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results

Cited by 40 publications

References 16 publications

Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus

Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus

Stem cell therapy for neurological disorders

Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients

Contact Info

Product

Resources

About